Matrixyl 3000: the two peptides behind the name

A family name, different peptides

Matrixyl is a trade name from ingredient supplier Croda, historically Sederma. The ingredient list on a serum uses standardized names called INCI names. Those names let you distinguish formulas that otherwise sound almost identical.

Three familiar members of the family use different peptides:

• Original Matrixyl: Palmitoyl Pentapeptide-4, a five-amino-acid peptide.
• Matrixyl 3000: Palmitoyl Tripeptide-1 plus Palmitoyl Tetrapeptide-7, a pair containing three and four amino acids respectively.
• Matrixyl Synthe'6: Palmitoyl Tripeptide-38, a different three-amino-acid peptide.

These mappings come from Croda's ingredient specifications. The numbers and suffixes distinguish products, not a ladder of proven performance. [1–3]

For Matrixyl 3000, the names break down like this:

Finding only Palmitoyl Tripeptide-1 does not identify the complete pair. Finding both names identifies the peptides used in Matrixyl 3000, though the ingredient list alone cannot confirm the supplier or the amount of each.

What the fatty-acid tail changes

The repeated word palmitoyl is doing real work. It describes a chemical group derived from palmitic acid, a 16-carbon fatty acid, attached to the peptide. This creates a molecule with a more oil-friendly region than the unmodified peptide. It is a change to the molecule itself, not a tiny capsule around it. [5]

The purpose is to alter how the peptide behaves in a formula and interacts with skin's lipid-rich outer barrier. But having a fatty-acid tail does not, by itself, establish how much peptide reaches deeper skin.

One study gives a concrete picture. Starr and colleagues used a molecular imaging method to track Pal-GHK in human skin samples outside the body. They detected it within the stratum corneum, the outermost barrier layer. Its signal decreased with depth and reached baseline at the boundary with the underlying epidermis. That experiment demonstrated distribution within the outer layer under the tested conditions; it did not show delivery to dermal fibroblasts. [6]

Pal-GHK also differs chemically from GHK-Cu. The former has a fatty-acid attachment; the latter is GHK complexed with copper. Sharing the GHK sequence does not make their study results interchangeable. Our GHK-Cu explainer covers the copper form, while the peptide-delivery guide explains how formulation affects delivery.

Why combine these two peptides?

Matrixyl 3000 was developed around the idea that short peptide signals can influence the material skin cells make. The relevant cells are fibroblasts, which help produce the extracellular matrix: the network around cells that includes collagen and other structural molecules.

The term matrikine describes a signaling fragment derived from that matrix. Cosmetic peptide research draws on this signaling concept, using selected sequences and chemically modified versions to investigate changes in cell activity. A peptide is therefore being studied as a message to a cell, rather than simply as extra raw material for making collagen. [7]

The specific reason to pair Pal-GHK with Pal-GQPR appears in Sederma's original patent experiments. Researchers exposed cultured human fibroblasts to the peptides separately and together, then measured matrix molecules after three days. Under those conditions, the combination increased type I collagen synthesis more than the sum of the separate responses. [8]

That is the useful meaning of synergy here: a measured interaction between these two peptides in that experiment. It explains why a blend was worth developing. It does not establish that combining any two peptide serums will produce the same interaction on a face.

Which studies tested which ingredient?

The word “Matrixyl” can conceal an important change of subject. These three studies answer different questions.

The 2005 trial tested the original pentapeptide

Robinson and colleagues studied pal-KTTKS, the peptide known as Palmitoyl Pentapeptide-4. Ninety-three women aged 35–55 used a moisturizer containing 3 ppm of that peptide on one side of the face and the same moisturizer without it on the other, in a randomized, double-blind, 12-week trial. The researchers reported improvements in fine lines and wrinkles compared with the control. The authors were affiliated with Procter & Gamble. [9]

This is relevant human research on the original Matrixyl peptide. It did not test the Pal-GHK and Pal-GQPR pair in Matrixyl 3000.

The 2015 paper examined the blend and skin structure

Mondon and colleagues evaluated a blend described as palmitoyl oligopeptide and palmitoyl tetrapeptide-7. The older oligopeptide wording appears in Sederma's Matrixyl 3000 documentation for Pal-GHK. Several authors, including the corresponding author, were affiliated with Sederma. [4,10]

The paper reports skin imaging with ultrasound and reflectance confocal microscopy. Ultrasound showed changes in a band just below the epidermis that returns relatively weak echoes; microscopy indicated improved matrix structure compared with placebo. These are measurements of skin structure, rather than a direct count of visible wrinkles. The accessible publisher abstract supports those qualitative findings; it does not supply enough detail to quote a wrinkle-reduction percentage. [10]

The 2023 trial tested a multi-peptide eye serum

Li and colleagues studied an eye serum containing 4% Matrixyl 3000 alongside Argireline and Eyeliss. Thirty-two women completed 28 days of twice-daily use. Instrument measurements found reductions in wrinkle number, depth and volume compared with their starting measurements. The study was funded by Dingmageili Biotechnology, and the formula was supplied by UNILIPO. [11]

This was a before-and-after study without a separate vehicle-control group. It provides evidence about that complete eye serum, but cannot tell us how much of the change came from Matrixyl 3000 or from either peptide individually.

Taken together, the research gives Matrixyl 3000 a specific experimental rationale and human findings worth understanding. The strongest reading is also the most precise: keep the original pentapeptide, the two-peptide blend and a finished multi-ingredient serum separate.

What a percentage on the bottle means

Croda supplies the standard Matrixyl 3000 ingredient as a mixture containing the two peptides plus glycerin, water and other formulation ingredients. Consequently, a study using “4% Matrixyl 3000” is describing an amount of that supplied blend, not 4% pure peptide. [1,11]

A percentage is useful only when you know what it measures. Two products labeled with different peptide-complex percentages may use different mixtures. The larger number alone cannot tell you which delivers more of a particular peptide, or which performs better.

When reading a serum's ingredient story, make three checks:

1. Find the pair. Look for Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7.
2. Identify the percentage. Is it the supplied blend or the peptides themselves?
3. Match the study. Did it test these two peptides, original Matrixyl, or a complete formula with several actives?

Those checks turn a familiar trade name into something you can actually interpret.